Shares of MEDNAX Inc (NYSE:MD) have been assigned a consensus rating of “Hold” from the thirteen analysts that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $38.36.

MD has been the topic of several analyst reports. Zacks Investment Research upgraded shares of HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd. Jefferies Financial Group lowered shares of from a “buy” rating to a “hold” rating in a research note on Thursday, April 11th. Finally, Citigroup set a $47.00 price objective on shares of Quanta Services and gave the company a “buy” rating in a research note on Friday, May 3rd.

NYSE MD traded down $0.07 during mid-day trading on Friday, hitting $23.65. The stock had a trading volume of 12,473 shares, compared to its average volume of 902,147. MEDNAX has a twelve month low of $23.05 and a twelve month high of $48.77. The company has a market capitalization of $2.07 billion, a PE ratio of 6.72, a price-to-earnings-growth ratio of 0.92 and a beta of 0.65. The stock’s 50 day moving average is $25.25. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.55 and a quick ratio of 2.55.

MEDNAX (NYSE:MD) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.63 by ($0.05). The company had revenue of $851.20 million during the quarter, compared to analysts’ expectations of $906.35 million. MEDNAX had a negative net margin of 1.05% and a positive return on equity of 9.82%. The business’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.89 EPS. On average, sell-side analysts anticipate that MEDNAX will post 3.11 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its stake in MEDNAX by 1.9% in the 4th quarter. BlackRock Inc. now owns 8,511,392 shares of the company’s stock valued at $280,874,000 after purchasing an additional 159,041 shares during the last quarter. Great West Life Assurance Co. Can increased its stake in MEDNAX by 2.6% in the fourth quarter. Great West Life Assurance Co. Can now owns 54,890 shares of the company’s stock valued at $1,682,000 after acquiring an additional 1,408 shares during the last quarter. Commonwealth Bank of Australia boosted its position in MEDNAX by 10.5% in the fourth quarter. Commonwealth Bank of Australia now owns 12,600 shares of the company’s stock valued at $415,000 after buying an additional 1,200 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in MEDNAX by 17.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,615,192 shares of the company’s stock valued at $86,301,000 after buying an additional 381,394 shares in the last quarter. Finally, Natixis Advisors L.P. boosted its position in MEDNAX by 38.5% in the fourth quarter. Natixis Advisors L.P. now owns 44,324 shares of the company’s stock valued at $1,462,000 after buying an additional 12,331 shares in the last quarter. Institutional investors own 91.60% of the company’s stock.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Featured Article: What is required to own or exchange cryptocurrency?

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.